-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 28, Fangsheng Pharmaceutical issued an announcement stating that the third extraordinary meeting of the fifth session of the board of directors of the company in 2022 reviewed and approved the "Proposal on the Transfer of Partial Equity Delivery of the Holding Subsidiary", agreeing that the company and DeVita, Baijun Medical, Kanglai Health, Ruijian Health, and Changsha Baijun signed the Supplementary Agreement (II) to the Convertible Bond Agreement on the issue of loans issued by DeVita Company
As of the disclosure date of this announcement, Baijun Medical or Changsha Baijun has not obtained the loan provided by DeVita Company; the "Supplementary Agreement (II) to the Convertible Bond Agreement" signed this time stipulates that before June 30, 2022, all parties If all the prerequisites have not been fulfilled, Devita will cancel the loan commitment.
At present, there are still uncertainties in the follow-up links of the company's transfer of part of the equity of Baijun Medical and the introduction of strategic investors
